Skip to content
Screener

Pfizer PFE Biopharma — D&A

Similar metrics at other companies

Becton, Dickinson and Company logo
BDXBioPharma Systems — D&A
$27M-15.6%
VAN
VANIBiopharm Division — D&A
$130K+31.3%
MYR Group logo
MYRGT&D — D&A
$15.92M+11.7%
Taboola.com Ltd. logo
TBLAD&A
$7.31M-21.7%
Brink's, Inc. logo
BCOD&A
$79.1M+32.3%
Flutter Entertainment logo
FLUTD&A
$399M+8.1%

Other financials

Income statement

See full
Revenue$15.0B+2.6%
Gross profit$10.9B+0.6%
Net income-$248.0M-109%
EPS (diluted)-$0.04-108%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+4.9%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$149.33B+9.8%
Enterprise value$212B+9.2%
P/E16.8×
P/S2.3×+0.2×

Profitability

See full
Gross margin73.2%+1.1pp
Net margin15.7%
FCF margin18%+8.8pp

Returns & leverage

See full
Return on equity10.6%
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: Pfizer’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 7:03 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000078003-26-000054
(MILLIONS)Three Months Ended / Total Revenues / March 29,2026Three Months Ended / Total Revenues / March 30,2025Three Months Ended / Earnings(a) / March 29,2026Three Months Ended / Earnings(a) / March 30,2025Three Months Ended / Depreciation and Amortization(b) / March 29,2026Three Months Ended / Depreciation and Amortization(b) / March 30,2025
Reportable Segment:
Biopharma(c)$14,161$13,441$6,838$7,069$348$331
Other business activities(d)289273(1,668)(1,384)7874
Reconciling Items:
Amortization of intangible assets(1,183)(1,211)1,1831,211
Acquisition-related items(504)(282)(1)
Certain significant items(e)(312)(1,407)34
$14,451$13,715$3,170$2,785$1,613$1,618

Item 1.

FAQ

What is Pfizer's biopharma — D&A?
Pfizer (PFE) reported biopharma — D&A of $348M in Q1 2026.
How has Pfizer's biopharma — D&A changed year-over-year?
Pfizer's biopharma — D&A increased by 5.1% year-over-year, from $331M to $348M.
What is the long-term trend for Pfizer's biopharma — D&A?
Over 4 years (2021 to 2025), Pfizer's biopharma — D&A has grown at a 15.0% compound annual growth rate (CAGR), from $789M to $1.38B.
What does biopharma — D&A mean?
The systematic allocation of the cost of tangible and intangible assets over their useful lives within the Biopharma segment. It reflects the consumption of capital investments, such as manufacturing facilities and acquired intellectual property.

Ask your AI about Pfizer's biopharma — d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude